Practical Approaches to the Treatment in High- or Very High-Risk MDS Patients

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.

Release Date: June 10, 2020
Expiration Date: June 10, 2021

Expected time to complete this activity as designed: 15 minutes
There are no fees for participating in or receiving credit for this online activity.

Program Overview

The subset of patients with high-risk MDS are often older patients who may not be eligible for more intensive treatments. In this activity, Dr. Larson will review the IPSS and IPSS-R criteria used to define these patients. He will also review risk factors associated with high-risk MDS and the goals of therapy. Lastly, he discusses key genetic mutations that should be addressed, including emerging agents that are of potential interest in this group of patients.

Target Audience

This activity is designed for multidisciplinary healthcare providers in the community setting, including hematologists, oncologists, pharmacists and other allied healthcare professionals who provide care to patients with myelodysplastic syndromes.

Learning Objectives

Upon completion of this educational activity, participants should be able to:

  • Describe guidelines and recommendations for assessing risk in patients with relapsed or refractory MDS
  • Outline efficacy and safety data from ongoing trials of therapeutic agents and regimens for patients with high-risk MDS
  • Develop treatment strategies for high-risk MDS patients that reflect the individual patient’s unique disease and clinical needs

Agenda

Practical Approaches to the Treatment in High- or Very High-Risk MDS Patients – Richard A. Larson, MD

Instructions for Participation and Credit

This activity is eligible for credit through June 10, 2021. After this date, this activity will expire and no further credit will be awarded.

  1. Read the target audience, learning objectives, and faculty disclosures.
  2. You may be asked to complete a short pre-test before accessing the educational content. This must be completed in order to move forward in the activity.
  3. Complete the educational content as designed.
  4. Complete the post-test. To receive a certificate, you must receive a passing score of 70%.
  5. Complete the activity evaluation survey to provide feedback and information useful for future programming.
  6. Certificates for CME may be printed immediately after successfully completing the post-test and activity evaluation. Pharmacist credit will be uploaded to CPE Monitor 4 weeks following receipt of a completed, qualified form.

Faculty Biography

Richard A. Larson, MD
Professor of Medicine
Hematology/Oncology
University of Chicago
Chicago, Illinois

Dr. Richard Larson received his medical degree from the Stanford University School of Medicine, and completed his postdoctoral training in internal medicine, hematology, and oncology at the University of Chicago. He was a fellow of the Leukemia Society of America. Dr. Larson is Professor of Medicine in Hematology/Oncology at the University of Chicago and Director of the Hematologic Malignancies Clinical Research Program. He was the Director of the Leukemia Clinical Research Program from 1983 to 2000, during which time he established the medical center's allogeneic blood and marrow transplant program.

Dr. Larson is the past chair of the Leukemia Committee of the Cancer and Leukemia Group B (CALGB) and is a member of the European LeukemiaNet committees for AML and CML. He has served as a Councillor and Officer of the American Society of Hematology, and represented ASH as a member of the National Cancer Policy Forum of the National Academy of Medicine. He has also served as a member of the Hematology Subspecialty Board of the American Board of Internal Medicine. Dr. Larson has served on the editorial boards of Blood, the Journal of Clinical Oncology, and Leukemia, and is an editor-in-chief for hematology for UpToDate. His research interests include clinical trials in hematologic malignancies and stem cell transplantation, experimental therapeutics, the determinants of response to therapy in leukemia and myelodysplastic syndromes, and the etiology of therapy-related myeloid neoplasms.

Accreditation

MediCom CME CREDIT
Accreditation Statement: MediCom Worldwide, Inc. is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Designation Statement: MediCom Worldwide, Inc. designates this enduring material for a maximum of 0.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
ACPE CPE CREDIT
MediCom Worldwide, Inc. is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This activity is acceptable for 0.25 contact hours of Continuing Education Credit. Universal Activity Number: 827-0000-20-014-H01-P. Knowledge-based CPE activity.

In order for CPE Monitor to authenticate credit, pharmacists/technicians must provide their e-Profile ID number from NABP and date of birth (in MMDD format) when registering for a CPE program. Please make sure to provide this information in your Member Profile accessed through the Member Center on the home page of this site.

International Pharmacy Preceptors and Canadian Pharmacists: If you are in need of e-Profile ID to participate in an ACPE approved activity, please contact NABP customer service for further assistance as special handling is necessary. NABP customer service can be reached at (847) 391-4406.

Disclosure

As an organization accredited by the Accreditation Council for Continuing Medical Education (ACCME), Accreditation Council for Pharmacy Education (ACPE) and California State Board of Registered Nursing, MediCom Worldwide, Inc. requires everyone who is a position to control the content of an educational activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines “relevant financial relationships” as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest. Accordingly, the following disclosures were made.

Faculty Disclosure

Dr. Richard Larson has received honoraria as a consultant from Amgen Inc., Celgene Corporation, CVS/Caremark, Epizyme, Inc., Novartis AG, and Takeda Oncology. He has received grant support related to research activities from Astellas Pharma US, Inc., Celgene, Cellectis, Daiichi Sankyo, Inc., Novartis, and Rafael Pharmaceuticals, Inc.

Planning Committee Disclosures

The individuals listed below from MediCom Worldwide, Inc. reported the following for this activity: Wilma Guerra, Program Director, Andrea Mathis, Project Manager, and Joan Meyer, RN, MHA, Executive Director, have no relevant financial relationships.

Peer Reviewer Disclosure

In accordance with MediCom Worldwide, Inc. policy, all content is reviewed by external independent peer reviewers for balance, objectivity and commercial bias. The peer reviewers have no relevant financial relationships to disclose.

If you have any questions or concerns regarding this activity, please contact MediCom Worldwide, Inc. at 1-800-408-4242 or email us at cmettille@medicaled.com.

Provided by MediCom Worldwide, Inc.
This activity is supported by educational grants from Astex Pharmaceuticals, Celgene Corporation, and Takeda Oncology.

©2020 MediCom Worldwide, Inc., 101 Washington St., Morrisville, PA 19067, 800-408-4242.
No portion of this material may be copied or duplicated without the expressed permission of MediCom Worldwide, Inc.

You need to be logged in to continue. Please Log In or Register using the box at the top right of this page.